Owing to the binding capacity to ɑvβ3
integrin overexpressed on
glioma, vasculogenic mimicry and neovasculature, the
peptide c(RGDyK) has been exploited pervasively to functionalize nanocarriers for targeted delivery of bioactives. The former study in our group substantiated the immunotoxicity of c(RGDyK)-modified
liposome, and this unfavorable immunogenicity is known to compromise blood circulation, targeting efficacy and therapeutic outcome. Therefore, we need to find a superior alternative
ligand in order to evade the exquisite immuno-sensitization. We developed mn by structure-guided
peptide design and retro-inverso isomerization technique, which was experimentally substantiated to have exceptional binding affinity to ɑvβ3
integrin. Besides mn does not have affinity toward normal liver cells and kidney cells, which c(RGDyK) possesses in a certain degree. Warranting that mn and c(RGDyK) anchored ɑvβ3, we formulated
peptide-tethered
liposomes and investigated in vivo bio-fate. Compared with c(RGDyK)-modified
liposome, mn-modified
liposome presented longer blood circulation and reduced ingestion by Kupffer cells with decreased retention in liver accordingly, benefitting from attenuated anti-
liposome IgG and
IgM response elicited by multiple sequential doses. Those merits strengthened the anti-
glioma efficacy of ɑvβ3-targeted
doxorubicin-loaded
liposomes, proving the importance of immunocompatibility in process of targeted drug delivery.